Condition

Prostate Cancer (CRPC)

ClinicalTrials.gov condition label

Clinical trials8

Recruiting3

Common interventions7

Lead sponsors shown7

Clinical trials

8 shown

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing ToxicityNCT07077239 · 2025-07-17

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617NCT06972628 · 2025-05-23

Study on Human Bioequivalence of Triprerelin Acetate for InjectionNCT06683066 · 2024-12-04

FAPI PET Imaging - An Exploratory StudyNCT07705074 · 2026-08-01

NOT_YET_RECRUITING

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT07214961 · 2025-11-03

ACTIVE_NOT_RECRUITING

Comparison of Peak Expiratory Flow Changes After Robot-Assisted Versus Open Radical ProstatectomyNCT07262073 · 2025-11-01

ACTIVE_NOT_RECRUITING

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsNCT02552121 · 2015-11-30

Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsNCT02001623 · 2013-11-30

Common interventions

Tisotumab Vedotin (HuMax-TF-ADC)DRUG2 [18F]FAPI-74 PET/CTDRUG1 AB001DRUG1 Administering Lutetium-177-PSMA-617 (PLUVICTO)DRUG1 DipherelineDRUG1 Surgical procedure: Robot-assisted laparoscopic radical prostatectomyDIAGNOSTIC_TEST1 Triprorelin for injectionDRUG1

Leading sponsors

Seagen Inc.2 Ankara City Hospital Bilkent1 ARTBIO Inc.1 Ebrahim S Delpassand1 Jonsson Comprehensive Cancer Center1 Martin Huellner1 The Affiliated Hospital of Qingdao University1

Trial status mix

RECRUITING3

ACTIVE_NOT_RECRUITING2

COMPLETED2

NOT_YET_RECRUITING1

Phase mix

PHASE15

PHASE24

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.